The Biotech Betting That Cancer Drugs Fail Because Nobody Looked at the Proteins

80% of cancer compounds that reach clinical trials fail. Yatiri Bio thinks the problem is that drug developers have been reading the wrong molecules - and it built a proteomics platform to prove it.